# A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

> **NCT04594798** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Rochester** · enrollment: 39 (estimated)

## Conditions studied

- DLBCL
- Lymphoma, B-Cell

## Interventions

- **DRUG:** Polatuzumab vedotin
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT04594798
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-20
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04594798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04594798, "A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04594798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*